Company intelligence / Profile preview

Multus

London, England, United Kingdommultus.bio ↗

Ownership: Private
Development stage: Commercial

Overview

Multus has launched commercial-scale animal-free, food-grade basal media such as DMEM/F12 and Proliferum B. These products replace fetal bovine serum in cultivated meat production with scalable, affordable alternatives developed using machine learning. The company operates an FSSC22000-certified manufacturing facility and collaborates with global food/feed companies to ensure supply chain stability. Its solutions support the scale-up of cellular agriculture by reducing cost and improving consistency.

Modalities: Growth factor proteinsRecombinant protein (for cell culture media)
Industry: Non-Drug Biotech

Partnerships

CARMA – UK’s Cellular Agriculture Manufacturing hub partnership memberSynbiCITE – Collaboration with academic institutions & industrial partners focused on synthetic biology commercialization

Beyond the preview

Go deeper on Multus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multus.

Explore the full profile